Zenas Biopharma (ZBIO) Competitors $8.17 +0.14 (+1.74%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsOwnershipSEC FilingsTrendsBuy This Stock ZBIO vs. CLDX, NVAX, OPK, INVA, GERN, MYGN, RIGL, EBS, VSTM, and VNDAShould you be buying Zenas Biopharma stock or one of its competitors? The main competitors of Zenas Biopharma include Celldex Therapeutics (CLDX), Novavax (NVAX), OPKO Health (OPK), Innoviva (INVA), Geron (GERN), Myriad Genetics (MYGN), Rigel Pharmaceuticals (RIGL), Emergent BioSolutions (EBS), Verastem (VSTM), and Vanda Pharmaceuticals (VNDA). These companies are all part of the "biotechnology" industry. Zenas Biopharma vs. Celldex Therapeutics Novavax OPKO Health Innoviva Geron Myriad Genetics Rigel Pharmaceuticals Emergent BioSolutions Verastem Vanda Pharmaceuticals Celldex Therapeutics (NASDAQ:CLDX) and Zenas Biopharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment. Does the MarketBeat Community favor CLDX or ZBIO? Celldex Therapeutics received 621 more outperform votes than Zenas Biopharma when rated by MarketBeat users. However, 100.00% of users gave Zenas Biopharma an outperform vote while only 75.24% of users gave Celldex Therapeutics an outperform vote. CompanyUnderperformOutperformCelldex TherapeuticsOutperform Votes62375.24% Underperform Votes20524.76% Zenas BiopharmaOutperform Votes2100.00% Underperform VotesNo Votes Which has higher earnings & valuation, CLDX or ZBIO? Celldex Therapeutics has higher revenue and earnings than Zenas Biopharma. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Zenas Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelldex Therapeutics$7.02M188.99-$141.43M-$2.45-8.16Zenas Biopharma$5M69.05-$148.39M-$3.55-2.33 Does the media favor CLDX or ZBIO? In the previous week, Zenas Biopharma had 6 more articles in the media than Celldex Therapeutics. MarketBeat recorded 10 mentions for Zenas Biopharma and 4 mentions for Celldex Therapeutics. Zenas Biopharma's average media sentiment score of 0.47 beat Celldex Therapeutics' score of 0.42 indicating that Zenas Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zenas Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is CLDX or ZBIO more profitable? Zenas Biopharma has a net margin of 0.00% compared to Celldex Therapeutics' net margin of -1,544.32%. Zenas Biopharma's return on equity of 0.00% beat Celldex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Celldex Therapeutics-1,544.32% -19.75% -18.86% Zenas Biopharma N/A N/A N/A Do analysts prefer CLDX or ZBIO? Celldex Therapeutics presently has a consensus target price of $54.33, suggesting a potential upside of 171.87%. Zenas Biopharma has a consensus target price of $40.00, suggesting a potential upside of 384.26%. Given Zenas Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Zenas Biopharma is more favorable than Celldex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89Zenas Biopharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryZenas Biopharma beats Celldex Therapeutics on 9 of the 16 factors compared between the two stocks. Remove Ads Get Zenas Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ZBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZBIO vs. The Competition Export to ExcelMetricZenas BiopharmaBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$345.26M$117.85M$5.63B$7.89BDividend YieldN/A3.69%4.57%4.01%P/E Ratio-2.333.2023.1218.72Price / Sales69.054,146.77384.2791.12Price / CashN/A13.0138.1634.64Price / BookN/A36.236.884.24Net Income-$148.39M-$87.82M$3.20B$247.06M7 Day Performance-0.84%-2.25%-2.57%-1.72%1 Month PerformanceN/A59.56%1.95%-5.34%1 Year PerformanceN/A83.52%9.80%-0.38% Zenas Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZBIOZenas BiopharmaN/A$8.17+1.7%$40.00+389.6%N/A$341.50M$5M-2.30N/AUpcoming EarningsCLDXCelldex Therapeutics1.5824 of 5 stars$20.02-3.7%$54.33+171.4%-52.2%$1.34B$7.02M-7.85150NVAXNovavax3.9712 of 5 stars$7.65-0.6%$18.00+135.4%+49.7%$1.23B$682.16M-3.391,990OPKOPKO Health4.3933 of 5 stars$1.79-1.4%$2.75+54.1%+62.6%$1.20B$713.14M-9.393,930Short Interest ↑Positive NewsINVAInnoviva4.4607 of 5 stars$17.42+0.5%$55.00+215.8%+16.9%$1.09B$358.71M25.28100Positive NewsGERNGeron4.4348 of 5 stars$1.71-2.6%$5.75+237.2%-50.2%$1.09B$76.99M-5.3670Short Interest ↓MYGNMyriad Genetics4.1335 of 5 stars$9.86-1.2%$21.89+122.0%-56.9%$900.31M$837.60M-7.582,700Analyst UpgradeRIGLRigel Pharmaceuticals2.9415 of 5 stars$20.00-2.7%$36.80+84.0%+23.4%$356.69M$179.28M142.64160EBSEmergent BioSolutions4.1988 of 5 stars$5.49-4.3%$14.33+161.3%+89.8%$299.13M$1.01B-1.341,600VSTMVerastem3.1024 of 5 stars$6.66-3.2%$13.88+108.4%-43.1%$295.97M$10M-2.0850Short Interest ↑Analyst RevisionVNDAVanda Pharmaceuticals4.3717 of 5 stars$4.78-0.9%$16.50+245.3%+18.3%$279.10M$198.77M-14.96290Positive News Remove Ads Related Companies and Tools Related Companies CLDX Alternatives NVAX Alternatives OPK Alternatives INVA Alternatives GERN Alternatives MYGN Alternatives RIGL Alternatives EBS Alternatives VSTM Alternatives VNDA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZBIO) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas Biopharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZBIO Stock Free ZBIO Stock Alerts